Stockreport

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea [Yahoo! Finance]

Ocugen, Inc.  (OCGN) 
PDF Potential sales milestones of $180 million or more in first 10 years of commercialization Royalties equaling 25% of net sales Ocugen to manufacture and supply OCU40 [Read more]